Pfizer has reported positive real-world data for Xiapex, its approved treatment for Dupuytren's contracture.
Information taken from real-life clinical practices has shown that Xiapex is able to deliver an improved range of movement to Dupuytren's contracture patients, affirming the conclusions of the clinical study Cord I.
It was also demonstrated that these positive treatment outcomes can be delivered via fewer injections and hospital visits than was thought to be the case following the phase III trials.
Meanwhile, analysis of recurrence data conducted during a separate study showed that treatment response to Xiapex can be maintained at three years.
Dr Gary Pess, an orthopaedic surgeon at the Drexel University School of Medicine in Philadelphia and the Central Jersey Hand Surgery, said: "This could potentially lead to a positive impact on healthcare costs associated with Dupuytren's contracture treatment in some countries."
Last week, the company reported positive data from a phase III study of the lung cancer drug Xalkori, showing the safety and efficacy of the treatment.See all the latest jobs in Pharmaceutical